PRL and neoplasm: Dopamine receptor type 2 (DRD2) represents the principle target for pharmacological therapy with dopamine agonists (DAs) due to its ability to induce tumor mass shrinkage and to regulate excessive hormone secretion in prolactin (PRL)-secreting PitNETs (3).